Format

Send to

Choose Destination
Pharmacol Ther. 2014 May;142(2):258-69. doi: 10.1016/j.pharmthera.2013.12.010. Epub 2013 Dec 19.

Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.

Author information

1
Division of Medical Oncology, University of Colorado Denver, Anschutz Medical Campus, United States; University of Colorado Cancer Center, University of Colorado Denver, Anschutz Medical Campus, United States. Electronic address: Todd.Pitts@ucdenver.edu.
2
Division of Medical Oncology, University of Colorado Denver, Anschutz Medical Campus, United States.
3
Division of Medical Oncology, University of Colorado Denver, Anschutz Medical Campus, United States; University of Colorado Cancer Center, University of Colorado Denver, Anschutz Medical Campus, United States.
4
Department of Pharmaceutical Sciences, University of Colorado Denver, Anschutz Medical Campus, United States; University of Colorado Cancer Center, University of Colorado Denver, Anschutz Medical Campus, United States.

Abstract

Cellular proliferation is a tightly controlled set of events that is regulated by numerous nuclear protein kinases. The proteins involved include checkpoint kinases (CHK), cyclin-dependent kinases (CDK), which regulate the cell cycle and aurora kinases (AURK) and polo-like kinases (PLK), which regulate mitosis. In cancer, these nuclear kinases are often dysregulated and cause uncontrolled cell proliferation and growth. Much work has gone into developing novel therapeutics that target each of these protein kinases in cancer but none have been approved in patients. In this review we provide an overview of the current compounds being developed clinically to target these nuclear kinases involved in regulating the cell cycle and mitosis.

KEYWORDS:

Cell cycle inhibitors; DNA damage response; Mitosis inhibitors; Nuclear kinase inhibitor

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center